GSK-2879552

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-2879552
Drug Alias NameGSK-28795522879552
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysine-specific histone demethylase 1 inhibitors
TargetsLysine-specific histone demethylase 1
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Small CellLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesCarcinoma, Small CellLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A